Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inborn error of long chain fatty acid 13-oxidation (FAO) with limited treatment options. Patients present with heterogeneous clinical phenotypes affect-ing predominantly heart, liver, and skeletal muscle. While VLCAD deficiency is a systemic disease, restoration of liver FAO has the potential to improve symptoms more broadly due to increased total body ATP production and reduced accumulation of potentially toxic metabolites. We explored the use of synthetic human VLCAD (hVLCAD) mRNA and lipid nanoparticle encapsulated hVLCAD mRNA (LNP-VLCAD) to generate functional VLCAD enzyme in patient fibroblasts derived from VLCAD deficient patients, mouse embryonic fibroblasts, hepatocytes isolated from VLCAD knockout (Acadvl-/-) mice, and Acadvl-/-mice to reverse the metabolic effects of the deficiency. Transfection of all cell types with hVLCAD mRNA resulted in high level expression of protein that localized to mitochondria with increased enzyme activity. Intravenous administration of LNP-VLCAD to Acadvl-/-mice produced a significant amount of VLCAD protein in liver, which declined over a week. Treated Acadvl-/-mice showed reduced hepatic steatosis, were more resistant to cold stress, and accumulated less toxic metabolites in blood than untreated animals. Results from this study support the potential for hVLCAD mRNA for treatment of VLCAD deficiency.

Automated summary

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is a genetic disease affecting the heart, liver, and skeletal muscle. Treatment using synthetic human VLCAD mRNA and lipid nanoparticle encapsulated hVLCAD mRNA (LNP-VLCAD) can generate functional VLCAD enzyme in patient cells and improve the metabolic effects of the deficiency.